Literature DB >> 27273143

Surgical procedures in patients with Glanzmann's thrombasthenia: case series and literature review.

Abhijeet Ganapule1, Punit Jain, Fouzia N Abubacker, Anu Korula, Aby Abraham, Joy Mammen, Biju George, Vikram Mathews, Alok Srivastava, Auro Viswabandya.   

Abstract

Glanzmann's thrombasthenia is a rare platelet function disorder with an autosomal recessive pattern of inheritance. Achieving haemostasis in such patients who undergo surgical procedures always poses a significant challenge. Herein we report six cases of Glanzmann's thrombasthenia, who underwent nine surgeries under the cover of platelet-rich concentrates with or without recombinant activated factor VII . Of these, five were major surgeries such as thyroidectomy, laparotomy, Hartmann's procedure, reversal of Hartmann's procedure and a complete dental extraction. All five procedures were successfully done without any major bleeding. The major cost incurred in these procedures is due to the large number of blood products used and recombinant activated factor VII if used.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27273143     DOI: 10.1097/MBC.0000000000000524

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Description and Clinical Management of Patients With Glanzmann's Thrombasthenia in a University Hospital, a Referral Center Specialized in Hemostasis, in Bogotá, Colombia.

Authors:  Maria H Solano; Karen Chaves; Claudia P Casas
Journal:  Cureus       Date:  2022-06-04

Review 2.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

3.  Glanzmann's thrombasthenia with spontaneous upper gastrointestinal bleeding: a case report.

Authors:  Zhenguo Qiao; Yi Chen; Wangtianyi Shi; Jun Yang; Yi Song; Jiaqing Shen
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.